Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One-and-Done radiation before lumpectomy? new trial tests feasibility

NCT ID NCT04234386

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a single, focused dose of radiation delivered by the GammaPod machine before lumpectomy surgery for early-stage breast cancer. The goal is to find a safe and effective dose that minimizes side effects and improves cosmetic outcomes. About 50 women with invasive ductal carcinoma will participate, receiving radiation at one of four dose levels before their tumor is removed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GammaPod radiation
What this could lead to
If successful, this could offer a shorter, more comfortable radiation treatment before surgery for early-stage breast cancer.
What could go wrong
This is an early-phase dose-finding study with only 50 participants, so results may not apply to all patients. Risks include infection or poor wound healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must sign consent for study participation. * Patients must be female with a diagnosis of invasive ductal carcinoma. Lobular histologies will not be included, because of difficulty in defining the extent of disease with imaging. * Patients must be deemed appropriate candidates for breast-conserving therapy (i.e., not pregnant, never had RT to the treated breast, breast size would allow adequate cosmesis after volume loss from partial mastectomy). * Tumor must not involve the overlying skin or underlying chest wall, based on imaging evaluation and/or clinical exam. * Greatest tumor dimension is \<3 cm based on US. MR imaging measurements can be included only if performed BEFORE the biopsy (postbiopsy measurements can be larger as a result of hematoma formation or increased edema). * Tumor must be unifocal. * Patients must be \> 45 years old. * The tumor must be visible on a CT scan. * Patients must undergo MR imaging for work-up to aid in tumor delineation and to rule out additional foci of disease. If additional foci of disease are found to be present, then these must be biopsied with negative results to proceed with treatment. * The tumor must be clinically and radiographically N0 (node negative). If a suspicious node is visualized, it must be biopsied with negative results. * Patients must be estrogen-receptor positive. * Patients must be HER2neu negative. * Patients must weigh \<150 kg (330 lb), which is the limit of the imaging loader. * Patients must be \<6'6" in height, again because of instrumentation limitations. * Patients must be able to lie prone for treatment. * Patients must have no lymphovascular invasion on biopsy. * Patients may be taking hormonal therapy prior to initiation of treatment. This will be documented. Exclusion Criteria: * Multicentric disease. * Prior RT to the involved breast. * Inability to fit into the immobilization breast cup because of breast size or other anatomic reasons. * Inability to obtain an adequate seal when using the immobilization breast cup. * Male sex. * Breast implants. * Patient cannot comfortably lie in the prone position (i.e., physical disability). * Patients who are planned to be treated surgically with a mastectomy. * Tumor \<5 mm from the skin surface or chest wall on clinical exam and/or radiographic imaging. * Tumor size \>3 cm. * Patients with psychiatric or addictive disorders that would preclude obtaining informed consent or study completion. * Patients who are pregnant or lactating (because of potential RT exposure to the fetus and unknown effects of RT in lactating women). * Patient unable to undergo MR imaging (e.g., because of known contrast reaction or concerns about contrast and existing health status). * Lymphovascular invasion on original biopsy. * Tumor histologies other than invasive ductal carcinoma (including invasive lobular carcinoma). * ER-negative tumors. * HER2neu-positive tumors. * Pure ductal carcinoma in situ (no invasive component). * Weight \>330 lb * Prior ipsilateral breast cancer. * Diffuse calcifications on mammogram (BIRADS 3, 4, 5).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baltimore Washington Medical Center

    RECRUITING

    Glen Burnie, Maryland, 21061, United States

  • Central Maryland Oncology Center

    RECRUITING

    Columbia, Maryland, 21044, United States

  • UMMC

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • Upper Chesapeake Health

    RECRUITING

    Bel Air, Maryland, 21014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.